Clinical trial company Lindus Health and US-based Thirty Madison have successfully completed the enrollment phase for a trial evaluating the effectiveness of Facet, a personalised dermatology telemedicine platform. Facet offers treatments for individuals with skin conditions such as atopic dermatitis, providing asynchronous evidence-based consultations, patient-reported monitoring, and messaging with healthcare providers. The platform's unique features include the use of before-and-after photos and patient reports to monitor progress.
The trial, conducted remotely, is managed by Lindus Health, overseeing data capture, statistical analysis, and project management through its proprietary EDC (Electronic Data Capture) system. Lindus Health had earlier secured a grant from Innovate UK Smart Grant and funding from investors to expedite clinical research trials using its technology platform and machine learning. Meri Beckwith, co-founder of Lindus Health, expressed excitement about the potential of the Facet platform to broaden access to treatment for eczema patients, highlighting the impact health tech companies can make on patient care.
The completion of trial enrollment coincides with a US study from the National Eczema Association, revealing a substantial interest among patients—almost 60%—in participating in clinical trials for the condition. However, the study also noted that fewer than 10% of patients have actually participated in such trials.
Neil Parikh, Chief Medical Officer of Thirty Madison, emphasised the platform's role in accelerating access to the care continuum, connecting specialists and supporting patients in their clinical journey while enabling participation in research studies to advance the treatment landscape.
Click here to read the original news story.